SONN实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 04:00):

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action...

Stats
今日成交量	6 161.00
平均成交量	104 046
市值	5.66M
EPS	$0 ( 2024-02-14 )
下一个收益日期	( $0.130 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.22
ATR14	$0.0170 (0.92%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-27	Rao Raghu	Buy	31 250	Warrant to Purchase Common Stock
2023-10-27	Rao Raghu	Buy	15 625	Common Stock
2023-10-27	Mohan Pankaj	Buy	68 750	Warrant to Purchase Common Stock
2023-10-27	Mohan Pankaj	Buy	34 375	Common Stock
2023-08-07	Markey John	Sell	0	Common Stock

INSIDER POWER
82.31
Last 88 transactions
Buy: 5 035 351 \| Sell: 2 861 714

Sonnet Biotherapeutics 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Sonnet Biotherapeutics 财务报表

Annual	2023
营收:	$147 805
毛利润:	$72 055.00 (48.75 %)
EPS:	$-18.14

Q1	2024
营收:	$18 626.00
毛利润:	$-1 348.00 (-7.24 %)
EPS:	$-0.310

Q4	2023
营收:	$37 255.00
毛利润:	$17 789.00 (47.75 %)
EPS:	$-2.10

Q3	2023
营收:	$36 850.00
毛利润:	$17 873.00 (48.50 %)
EPS:	$-2.96

Financial Reports:

No articles found.

Sonnet Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.